Jefferies rates Genzyme at buy

Genzyme Corp. was given a buy rating by Jefferies & Co., Inc. analyst Adam Walsh. Encouraged by accelerated product growth in the second quarter after weak first-quarter sales, the analyst is optimistic that the second half of the year will be a strong and steady period. The addition of Myozyme should help, as should the growth of Synvisc and Fabrazyme. Shares of the Cambridge, Mass.-based biotechnology company were up 20 cents, or 0.32%, at $62.94 on volume of 4,563,921 shares versus the three-month running average of 3,297,340 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.